How do I respond to an FDA Additional Information (AI) request?

When a sponsor of a Class II medical device, such as a diagnostic imaging software, receives a complex Additional Information (AI) request from the FDA, what is a comprehensive strategic framework for managing the response to maximize the chances of a favorable substantial equivalence (SE) decision? Beyond the immediate task of answering the questions, this involves several critical stages. First, during the initial triage phase, how should regulatory teams methodically dissect the AI letter to categorize each FDA deficiency? What criteria can be used to distinguish between a simple request for clarification, a need for re-analyzing existing data, or a major gap requiring new performance testing (e.g., further software validation or cybersecurity vulnerability assessments)? Second, in developing the response strategy, what key factors help determine whether it is more effective to conduct new testing versus preparing a robust scientific justification based on existing data, published literature, or established standards? For ambiguous or seemingly unfeasible requests, what is the appropriate process and rationale for engaging with the FDA reviewer, for example through a Submission Issue Request (SIR), to seek clarification without delaying the process unnecessarily? Finally, regarding documentation and presentation, what are the best practices for structuring the AI response document itself? How can sponsors ensure each response is a complete, standalone package that directly and unambiguously addresses the specific FDA question, often by restating the question before providing the detailed answer, new data, or justification? How should this new information be integrated with the original 510(k) to present a cohesive submission file for the reviewer, thereby minimizing the risk of follow-up questions or a Not Substantially Equivalent (NSE) outcome?